VLDLR and nonpapillary renal cell carcinoma: Our research on ccRCC has found that the LXR agonist LXR623 downregulates the low-density lipoprotein receptor (LDLR) protein and upregulates the expression of ABCA1, which leads to reduced levels of intracellular cholesterol and enhanced apoptosis in ccRCC.